Caliway's CBL-514 Meets Primary Endpoint in Dercum's Disease Trial
Image
New Taipei City – September 23, 2026 -- Caliway Biopharmaceuticals (TWSE: 6919) said on September 21 that its Phase 2 CBL-0202DD trial of CBL-514 met its primary efficacy endpoint, delivering statistically significant pain reduction in patients with Dercum's Disease compared with placebo, in both the Full Analysis Set (FAS) and Per-Protocol (PP) populations.
CBL-514 Cuts Pain Scores by 3.1 Points at Week 20 Versus Placebo
In the FAS population, patients treated with CBL-514 achieved a mean pain-score reduction of 3.1 points at Week 20, versus 1.9 points for placebo (p=0.005). In the PP population, the same 3.1-point reduction was measured against a 1.4-point placebo response (p=0.0002).